Recently, Eli Lilly announced that it would be cutting the prices of its insulin products by 70%, CNN reported. This news comes after years of public outcry over the high cost of insulin, which has been dubbed the “silent killer” due to the deadly consequences of rationing the life-saving medication.
Featured News
Federal Judge Narrows Yardi Antitrust Lawsuit, Dismisses Out-of-State Defendants
Apr 2, 2026 by
CPI
Italian Regulator Fines Revolut €11 Million Over Alleged Misleading Practices
Apr 2, 2026 by
CPI
Justice Department Challenges Decision Stopping Anthropic AI Ban
Apr 2, 2026 by
CPI
Ivy League Wins Antitrust Case Over Athletic Scholarship Policy
Apr 2, 2026 by
CPI
Maine Set to Become First State to Ban AI Data Centers
Apr 2, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers